Elliott Investment Management Takes Multibillion-Dollar Stake in Synopsys 
Sinopec Posts 36.8% Net Profit Drop in 2025 Amid Weak Petrochemical Margins and Energy Transition Pressures 
Virgin Australia Adjusts Fares Amid Rising Aviation Costs and Middle East Tensions 
EA's $15B Debt Offering Draws $25B in Investor Demand Amid Credit Market Turmoil 
HSBC Considers Cutting 20,000 Jobs Amid AI-Driven Transformation 
FEMSA Cuts Jobs at Spin Fintech Unit, Refocuses Strategy on Oxxo Stores 
Cyberattack on Stryker Triggers U.S. Government Warning Over Microsoft Intune Security 
Xiaomi Shares Drop After SU7 Launch as Margin Concerns Weigh on Investors 
Jeff Bezos Eyes $100 Billion Fund to Transform Manufacturing With AI 
Amazon's "Transformer" Phone: Can It Succeed Where Fire Phone Failed? 
Apple Defies China's Smartphone Slump with Strong Early 2026 Sales 
Micron Technology Beats Q2 Earnings Estimates, Issues Strong AI-Driven Outlook 
Netflix Eyes South Korea for More Live Events as BTS Concert Livestream Approaches 
Palantir's Maven AI Earns Pentagon "Program of Record" Status, Reshaping Military AI Strategy 
J.P. Morgan Now Expects Two ECB Rate Hikes Amid Inflation Pressures 
FCC Approves $3.54B Nexstar-Tegna Merger, Waiving Broadcast Ownership Cap 
Judge Dismisses Sam Altman Sexual Abuse Lawsuit, But Sister Can Refile 
Reckitt Benckiser is considering the sale of its subsidiary, Mead Johnson Nutritionals, which is based in China. It was said that the British multinational consumer goods company is eyeing at least $2 billion for the deal.
Sources who have knowledge on the matter told Reuters that Reckitt Benckiser already hired the American financial services company, Morgan Stanley, to review its Mead Johnson infant formula unit in Greater China. The insiders were not names since the information shared is confidential.
The plans for the sale of Mead Johnson’s infant formula
Based on the report, Reckitt Benckiser could commence the sale process any time within the second quarter of this year. As soon as the bank receives feedback or recommendation from potential buyers, the sale will begin.
Then again, all the interested parties have been warned that Reckitt Benckiser has not made any definite decision yet, and business valuation could still change because of the negative effects of the COVID-19 pandemic. Moreover, in February, it was said that the company is exploring its other options on how to handle Mead Johnson’s infant formula unit.
In any case, Reckitt Benckiser acquired Mead Johnson in 2017 for $16.6 billion in 2017. The infant formula-maker gave the company billions from the sale of its leading milk brands that include Lactum, Enfapro, and Enfamil.
Why Mead Johnson is being sold
Reckitt Benckiser’s chief executive officer, Laxman Narasimhan, said that there is a big decline in sales in China which makes up 6 percent of the group sales. The reason for the dive is the closure of the Hong Kong border that is taking a long time to re-open due to coronavirus.
Also, the birth rate in one of the most populous countries in the world has gone down as well, so there is less infant to feed with the formula from Mead Johnson. Lastly, Chinese locals have been choosing to buy imported milk due to the 2008 milk contamination controversy scandal. In fact, it was noted that on China’s leading e-commerce platform, JD.Com, the top four best-selling brands of infant formula are all from foreign labels.
